ENGLEWOOD,
Colo., Feb. 6, 2024 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, rehabilitation, and patient
monitoring, today announced that it has received clearance from the
U.S. Food and Drug Administration ("FDA") for the next generation
M-Wave Neuromuscular Electrical Stimulation ("NMES") device.
NMES treatments have several uses, including
aiding recovery from surgery, managing chronic conditions, and even
enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave,
which has been fundamental in NMES treatments across the U.S. since
1998. The E-Wave was the most powerful and versatile muscle
stimulation device on the market for over two decades and the
M-Wave builds on that history of performance with a more intuitive
design and additional functionality.
"The M-Wave introduces the next evolution in NMES
devices, allowing for more customizable treatments within clinical
and home settings," said Thomas
Sandgaard, CEO at Zynex Medical. "Our Product Management
team has incorporated patient and physician feedback when designing
the new M-Wave. The user-friendly interface and ease of use when
designing a custom electrotherapy regimen will encourage an even
broader adoption of Zynex's therapeutic products."
The M-Wave is designed to improve the way
patients manage their neuromuscular conditions. With advanced
features and a user-friendly design, the M-Wave allows patients to
be treated quickly in a clinical or home setting. The compact and
lightweight design of the M-Wave ensures portability and easy
integration into patients' recovery routines.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures,
markets, and sells medical devices used for pain management and
rehabilitation as well as non-invasive fluid, sepsis, and
laser-based pulse oximetry monitoring systems for use in hospitals.
For additional information, please visit: www.zynex.com.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. our results of operations and the
plans, strategies and objectives for future operations; the timing
and scope of any potential stock repurchase; and other similar
statements.
Words such as "anticipate," "believe,"
"continue," "could," "designed," "endeavor," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "predict,"
"project," "seek," "should," "target," "preliminary," "will,"
"would" and similar expressions are intended to identify
forward-looking statements. The express or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward looking statements. The Company makes no express
or implied representation or warranty as to the completeness of
forward-looking statements or, in the case of projections, as to
their attainability or the accuracy and completeness of the
assumptions from which they are derived. Factors that could cause
actual results to materially differ from forward-looking statements
include, but are not limited to, the need to obtain CE marking of
new products; the acceptance of new products as well as existing
products by doctors and hospitals, larger competitors with greater
financial resources; the need to keep pace with technological
changes; our dependence on the reimbursement for our products from
health insurance companies; our dependence on third party
manufacturers to produce our products on time and to our
specifications' implementation of our sales strategy including a
strong direct sales force, the impact of COVID-19 on the global
economy; market conditions; the timing, scope and possibility that
the repurchase program may be suspended or discontinued; economic
factors, such as interest rate fluctuations; and other risks
described in our filings with the Securities and Exchange
Commission.
These and other risks are described in our
filings with the Securities and Exchange Commission including but
not limited to, our Annual Report on Form 10-K for the year
ended December 31, 2022 as well as our quarterly reports
on Form 10-Q and current reports on Form 8-K. Any forward-looking
statements contained in this press release represent Zynex's views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Zynex explicitly disclaims any
obligation to update any forward-looking statements, except to the
extent required by law.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594
View original
content:https://www.prnewswire.com/news-releases/zynex-receives-fda-clearance-for-its-next-generation-nmes-device-302054404.html
SOURCE Zynex
